cyrilzakka/clinical-trials huggingface dataset:
Thymic Function in Patients With COVID-19

The main clinical manifestation associated with SARS-CoV-2 infection is an influenza-like illness that follows the infection of the respiratory tract. In a few percent of infected people, inflammation of the lungs leads to severe pneumonia that requires hospitalization, in intensive care units for the more severe cases. Despite intensive care, a fatal outcome occurs in 6% and 12% of women and men over 80 years of age hospitalized for severe COVID, respectively.

Factors associated with a higher risk of death in patients with SARS-CoV-2 include age and low circulating lymphocyte counts. Significant lymphopenia is indeed frequently observed in patients with severe COVID-19 and both phenotypic and functional changes in antiviral T cells have been correlated with the severity of COVID-19.

The thymus, the organ that produces T lymphocytes, undergoes progressive physiological involution with age. However, in the elderly, rare cases of thymic hyperplasia are reported in autoimmune diseases or cancers, or are observed in response to deep lymphopenia, whether or not associated with sepsis.

This cohort of patients treated for a SARS-CoV-2 infection could allow to better understand the role of the thymus in this pathology.


Eligibility Criteria:
Inclusion Criteria:

Cases :

* Patients with confirmed COVID-19 infection
* Hospitalized for COVID-19 infection
* Having signed a written informed consent form
* Affiliation to the social security system

Controls :

* Non-COVID-19 patients
* Hospitalized for other reasons
* Age and sex-matched controls
* Having signed a written informed consent form,
* Affiliation to the social security system

Exclusion Criteria:

* Autoimmune disease
* HIV, Hepatitis B or Hepatitis C
* Pregnant or breastfeeding women
* A mental or linguistic inability to understand the study
* Patient under protection of the adults (guardianship, curators or safeguard of justice)
FemBloc® Permanent Contraception - Early Pivotal Trial

Prospective, multi-center, international, non-randomized, two-arm study of subjects undergoing either FemBloc or laparoscopic bilateral tubal sterilization (Control). The FemBloc group total study duration will be approximately 65 months. The laparoscopic tubal sterilization (Control) group total study duration will be approximately 62 months.


Eligibility Criteria:
Inclusion Criteria:

* Female, 21 - 45 years of age desiring permanent birth control
* Sexually active with male partner
* For FemBloc Arm:

  * Regular menstrual cycle for last 3 months or on hormonal contraceptives
* For Control Arm:

  * Undergoing planned laparoscopic bilateral tubal sterilization

Exclusion Criteria:

* Uncertainty about the desire to end fertility
* Known or suspected pregnancy
* Prior tubal surgery, including sterilization attempt
* Prior endometrial ablation
* Presence, suspicion, or previous history of gynecologic malignancy
* Abnormal uterine bleeding requiring evaluation or treatment
* Scheduled to undergo concomitant intrauterine procedures at the time of procedure(s)
Effect of Hormonal Contraception on Lower Urinary Tract Symptoms& Sexual Function

Effect of hormonal contraception on lower urinary tract symptoms\& sexual function

It is generally accepted that female sex hormones influence the morphology and physiology of vaginal tissues. Peripheral estrogen affects urogenital connective tissue composition and structure, vaginal blood flow, and thickness of vaginal epithelium. Estrogen and progestagen receptors are also abundantly present in the lower urinary tract, which has the same embryonic origin as the vagina. decline in circulating estrogen levels may result in atrophy of vaginal, urethral and bladder trigonal epithelium, as well as initiate metabolic changes in the subepithelial supportive tissues. This process forms the biological rationale for the common clinical practice of prescribing hormone treatment to menopausal women with lower urinary and genital tract symptoms.

Contrary to widespread belief, the Womens Health Initiative (WHI) randomised trial showed that menopausal hormone therapy with conjugated estrogen alone, or in combination with progestagen, increased the risk of de novo or aggravated urinary incontinence after one year of treatment. In premenopausal women, oral contraception is the most common source of hormone intake but very few studies have endeavored to determine the effects of oral contraception on premenopausal urinary incontinence. The aim of this nationwide cohort study was to assess the influence of contraceptives on the risk for lower urinary tract dysfunction in young female.at is time-related with the beginning of hormonal contraception, health care providers should give information about other methods and try to switch them to a method less associated with sexual dysfunction. However, there are contradictory results between the different studies regarding the association between sexual dysfunction and hormonal contraceptives, so it could be firmly said that additional research is needed.

Meanwhile, it could be said that hormonal contraception has been associated with different alterations in sexual functioning.

To conclude, a multidisciplinary approach to the management of female sexual dysfunction is mandatory, and health care providers should give lifestyle counselling apart from proposing different treatment options. An adequate relationship with the patient, as well as the routine monitoring of possible sexual dysfunction, are essential in addressing these difficulties. Undoubtedly, the best contraceptive is one that fulfills the women's needs with acceptable side effects and agreed with the prescribed

Eligibility Criteria:
Inclusion Criteria:

1. Women taking hormonal contraception e.g cocs .pops.implanon\&.injectable contraception
2. Women has good regular marital life

Exclusion Criteria:

1. female has organic urinary dysfunction
2. female has mental\& psycological dysfunction
3. chronic disease DM.hypertension. chronic renal disease
4. prolapse
5. previous perineal \&vaginal correlation surgery
6. women taking any treatment for urinary tract infection \&sexual dysfunction
Long Term Arrhythmia Risk and Cardiovascular Events in Hematopoietic Stem Cell Transplant

The purpose of this study is to better understand the following aims:

1. Aim 1: To evaluate the rate of recurrent Atrial Fibrillation (AF)/Atrial Flutter (AFL) in hematopoietic stem call transplant (HCST) patients with incident AF/AFL identified during the initial 30 days of the transplant
2. Aim 2: To evaluate incident episodes of 1) stroke/TIA; 2) other thromboembolic events (not stroke/TIA); 3) Heart failure events; 4) Ischemic heart events
3. Aim 3: To evaluate overall implantation safety in this population

We propose a registry study in hematopoietic stem cell transplant (HSCT) patients with incident atrial fibrillation/atrial flutter (AF/AFL) during the initial 30 days of transplant who will be implanted with the Medtronic Reveal Linq Implantable Cardiac Monitor (ICM) within 90 days of HSCT. We will evaluate the rate of recurrent AF/AFL as well as incident episodes of major cardiovascular events and the safety of ICM implantation in this population.

Eligibility Criteria:
Inclusion Criteria:

1. Age ≥18
2. CHADS-VASc ≥ 2
3. Recovery of platelets to \>50,000 within 90 days of incident atrial fibrillation (AF) diagnosis
4. Discharge from the incident stem cell transplant (SCT) hospitalization
5. Normal sinus rhythm at the time of consent

Exclusion Criteria:

1. Prior history of atrial fibrillation (AF) or atrial flutter
2. CHADS-VASc \<2
3. Platelets \<50,000 after 90 days post transplantation
4. Continued SCT hospitalization at 90 days
5. Inability to receive anticoagulation
6. AF or other arrhythmia at the time of consent
7. Current use of a class IC or III antiarrhythmic medication
8. Inability to provide informed consent/significant cognitive impairment
9. Expected survival less than one year.
Effect of Addition of Fentanyl or Dexamethasone or Both to Bupivacaine in Paravertebral Block for Patients Undergoing Major Breast Surgery

This study evaluated the analgesic efficacy of fentanyl and dexamethasone in combination with bupivacaine for single-shot paravertebral block (PVB) in patients undergoing major breast surgery.

This study evaluated the analgesic efficacy of fentanyl and dexamethasone in combination with bupivacaine for single-shot paravertebral block (PVB) in patients undergoing major breast surgery.

Patients will receive ultrasound guided paravertebral block and stratified into 3 groups according to medication used :

Group 1 : bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg Group 2 : bupivacaine (0.5%) 20 ml , dexamethasone 4 mg Group 2 : bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg , dexamethasone 4 mg

Eligibility Criteria:
Inclusion Criteria:

* Age: 18-70 years.
* Sex: females
* ASA physical status: I-II.
* Operation: major breast surgery

Exclusion Criteria:

* - Patient refusal.
* History of cardiac disease, psychological disorders, respiratory diseases including asthma, renal or hepatic failure.
* Coagulation disorders.
* Infection at the puncture site
* Allergy to study medications.
* Chronic use of pain medications.
* Respiratory tract in¬fection within the last 2 weeks.
* Neurological deficit
Precision Approach to PPI Therapy in Gastroesophageal Reflux Disease

This study plans to learn more about reflux associated laryngeal symptoms, and more efficient ways to diagnose and treat this condition.

Reflux associated laryngeal symptoms, coined "laryngopharyngeal reflux", occurs when gastro-esophago-pharyngeal reflux contributes to chronic laryngeal symptoms such as throat clearing, sore throat and dysphonia. Over the past 25 years, Reflux associated laryngeal symptoms has been increasingly, and often incorrectly, diagnosed and has emerged as a point of controversy and confusion.

Eligibility Criteria:
Inclusion Criteria:

* Age 18-89 years male and female,
* \>8 weeks of symptoms of sore throat, throat clearing, and/or voice hoarseness,
* naïve to PPI or able to stop for 8 weeks

Exclusion Criteria:

* Laryngeal mass lesion on laryngoscopy;
* Pregnant;
* Unable to consent in English;
* Imprisoned;
* PPI intolerance;
* Contraindication to UESAD use per manufacturer guidelines which include:

  * Patients with implants or implant parts that reside in the area where UESAD is applied.
  * Patients with an implanted pacemaker, implanted cardioverter defibrillator (ICD), vagus nerve stimulator, or other such similar devices implanted in the neck.
  * Patients diagnosed with glaucoma.
  * Patients who had a malignancy of the neck, including neck surgery.
  * Patients that may have an altered mental status including due to the use of sedative drugs or narcotics.
  * Patients with carotid artery disease, thyroid disease, a history of cerebrovascular disease, or any disorder of connective tissues (e.g., Marfan's Syndrome or Ehlers-Danlos Syndrome).
  * Patients who use nocturnal NIV machines such as CPAP or BiPAP.
Safety Study of FLP Injection to Treat Tumor Patients

The purpose of this study is to determine the tolerance and maximum tolerated dose (MTD) for FLP Injection with multiple dose in tumor patients.

To determine the tolerance and MTD for FLP Injection with multiple dose in tumor patients.

To test clinical pharmacokinetics (PK) and PK parameter

Eligibility Criteria:
Inclusion Criteria:

* aged from 18 to 70 years old, male or female;
* histologically or cytologically proven advanced malignant solid tumors;
* cancer patients after conventional treatment failure and lack of effective treatment, or patients refusing effective treatment of existing practices;
* patients receiving the last treatment (chemotherapy, radiotherapy, biological therapy, targeted therapy, or other study drugs) for at least 4 weeks;
* expected survival time\>3 months;
* ECOG score 0-1

Exclusion Criteria:

* viral activity in patients
* allergic to drugs or excipients;
* hypersensitivity to paclitaxel injection patients;
* HIV antibody positive, or suffering from other acquired and congenital immune deficiency disease, or history of organ transplantation;
* neutrophil count \<1.5 × 109 / L, platelets \<100 × 109 / L, or hemoglobin \<90g / L;
* normal serum creatinine higher than 1.5 times the upper limit of reference range or the muscle of liver clearance \<60ml/min;
* no case of liver ALT or AST\> 2.5 times the upper limit of normal, or liver metastases than normal under the ALT or AST 5 times upper limit of reference range;
* fever or body temperature above 38 ℃ can be clinically significant impact on clinical trials of active infection;
* medications failed to control hypertension (systolic pressure is over 160 mmHg or diastolic pressure over 100mmHg);
* significant cardiovascular abnormalities (such as myocardial infarction, superior vena cava syndrome), or clinically significant arrhythmias (such as long QT syndrome, Corrected QTc not be measured or ≧ 480 ms);
* calcium, potassium, magnesium ions below the lower limit of normal;
* \> I-level peripheral neuropathy
* Prior to the toxicity of anticancer therapy has not been restored or not from the surgery before full recovery;
* bone metastases for the primary lesion of palliative radiotherapy;
* any clinical problems can not control (such as the serious mental, neurological, cardiovascular, respiratory and other diseases);
* a tumor metastasis, or a variety of mental disorders center; no history of asthma;
* pregnancy or breast-feeding women
Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax

Single center, open-label, phase 2 study to determine the efficacy of cirmtuzumab consolidation in patients with measurable disease on venetoclax.

This is a phase 2 study to test whether cirmtuzumab in combination with venetoclax given as consolidation therapy can decrease the number of cancer cells that may be left in the bone marrow or in the blood in patients who have been treated with venetoclax for at least one year. Consolidation therapy is given after initial cancer treatment to further reduce the number of cancer cells that may be left in the body. Cirmtuzumab, a monoclonal antibody that inhibits receptor tyrosine kinase like orphan receptor (ROR1) signaling and stemness, may be effective in reducing the risk of disease progression in patients with detectable minimal residual disease (MRD) after treatment with venetoclax.

Eligibility Criteria:
Inclusion Criteria:

* Must have detectable CLL/SLL (\> 0.01% leukemia cells present)
* Must have received at least 12 months of venetoclax.
* Patients may be receiving venetoclax at the time of screening and study entry.
* Patients who have discontinued venetoclax more than 6 months prior to study entry must still have a disease burden meeting criteria for low risk of TLS (i.e. no lymph node greater than 5 cm in diameter; absolute lymphocyte count less than 25 k/uL)

Exclusion Criteria:

Evidence of other clinically significant uncontrolled condition(s) including, but not limited to:

* Uncontrolled and/or active systemic infection (viral, bacterial or fungal)
* Chronic hepatitis B virus (HBV) or hepatitis C (HCV) requiring treatment. Note: subjects with serologic evidence of prior vaccination to HBV (i.e. hepatitis B surface (HBs) antigen negative, anti-HBs antibody positive and anti-hepatitis B core (HBc) antibody negative) or positive anti-HBc antibody from intravenous immunoglobulins (IVIG) may participate.
* Child class B or C cirrhosis

Treatment with any of the following within 7 days prior to the first dose of cirmtuzumab:

* Steroid therapy for anti-neoplastic intent
* Biologic agent (monoclonal antibody) within 30 days for anti-neoplastic intent.
* Chemotherapy (purine analog or alkylating agent) or target small molecule agent within 14 days or 5 half-lives (whichever is shorter), or has not recovered to less than CTCAE grade 2 clinically significant adverse effect(s)/toxicity(s) of previous therapy.
* CLL therapy, aside from venetoclax.
* History of other malignancy that could affect compliance with the protocol or interpretation of results (example: patients with a history of curatively treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix are generally eligible.)
* Women who are pregnant or lactating
FIO2 Influences SvO2 Interpretation and Fick-based Cardiac Output Assessment

In this study, the investigators sought to clarify the influence of FIO2 levels on the variables in the Fick equation and then assessed the influence of each variable on the accuracy of Fick-CO measurements in patients undergoing cardiac surgery.

Patients who are aged ≥20 years, are undergoing planned elective cardiac surgery, and provided signed informed consent are included in the present study. Any patients with an intra-cardiac shunt are excluded.

The patients are randomly assigned to 2 groups: FIO2 \<0.7 or FIO2 \>0.85. And during the surgery, the oximeter values are kept ≥98%. Intra-operatively, FIO2, PaO2, SaO2, SvO2, PvO2, Hb, blood pH values, body temperature and TD-CO are recorded.

Eligibility Criteria:
Inclusion Criteria:

* undergoing planned elective cardiac surgery
* agree to sign informed consent

Exclusion Criteria:

* intra-cardiac shunt
Prognostic Value of Tumor Deposits for Patients With Papillary Thyroid Carcinoma

Tumor deposits (TD), nodules in the peritumoral adipose tissue with no architectural residue of lymph node, which is a definition often being confusing to the extranodal extension (ENE), have been described in several malignancies and linked to a worse prognosis. In gastric cancer and colon cancer, TD and ENE should be distinguished and collected separately in 8th AJCC manual. However, in thyroid cancer, TD as a collection variable was absence in both the 8th AJCC manual and the 2015 ATA guideline. This is a study that revealed the presence of TD by reviewing a large number of papillary thyroid carcinoma (PTC) specimens and explored its prognostic value by constructing a nomogram to accurately predict disease-free survival in PTC patients.


Eligibility Criteria:
Inclusion Criteria:

(1) patients with histopathologically confirmed PTC and sections stored in the pathology department; (2) patients underwent lobectomy or total thyroidectomy and central lymph node dissection with or without lateral neck dissection; (3) patients cooperated to provide follow-up information after surgery.

Exclusion Criteria:

(1) patients with previous history of neck irradiation or other systematic cancers; (2) patients died of unrelated diseases.
TMS Electrochemotherapy for Glioblastoma Multiforme

The proposed project aims to develop novel electrochemotherapeutic treatment of glioblastoma multiforme (GBM). Standard treatment has limited effect on survival and quality of life. Electrochemotherapy is a novel and promising treatment, which has demonstrated convincing results in the treatment of various types of carcinoma. The treatment is based on a combination of electrical current stimulation of tumor cells and simultaneous administration of chemotherapeutic drugs. Electrochemotherapy works by inducing an electrical current between implanted electrodes in the tumor tissue, causing electroporation of the cancer cell membranes, and thereby increasing the cellular permeability and drug uptake. Electrochemotherapy has proven to be an efficient way of considerably increasing the potency of the chemotherapeutic drug bleomycin in malignant cells in skin tumors and carcinoma metastases, and thereby increasing cytotoxicity of the drug locally in the tumor tissue. This allows for treatment with lower doses of chemotherapeutic drugs and more defined, local area of effect, thus decreasing systemic effects. The investigators propose to use a novel non-invasive and safe technique called focused transcranial magnetic stimulation (focused TMS) to induce electrical current in the tumor tissue. TMS is a safe and widely implemented technology used to treat multiple neurological diseases such as pain, depression and stroke. Studies have shown that effective electroporation of cell membranes can be obtained using induction of electromagnetic fields in a cell suspension, and new focused TMS further enables focused treatment of selected brain regions without surgical intervention and, thereby focusing chemotherapeutic treatment to pathological tissue and avoiding surgery related brain tissue damage. Additionally, TMS transiently increases blood-brain barrier permeability, theoretically allowing increased uptake of chemotherapeutic drugs in the target area. This addresses a significant challenge in the treatment of brain cancer, as most cytotoxic drugs have fairly limited ability to pass the blood brain barrier.

The intention of this research project is to investigate the therapeutic potential of focused TMS as an alternative non-invasive source of current induction and thereby means to treat several types of brain cancer with electrochemotherapy.


Eligibility Criteria:
Inclusion Criteria:

* Newly diagnosed and histologically confirmed glioblastoma multiform
* MGMT gene methylation
* If age \< 70, eligibility to comply with the Stupp radio chemotherapy regimen
* If age \> 70, eligibility for stand alone chemotherapeutic treatment
* Ability to comply with the proposed TMS treatment
* Use of validated anti-conception for fertile female participants in concordance with guidelines provided by the Danish Health and Medicines Authority

Exclusion Criteria:

* Pregnancy or nursing
* Other conditions that may contraindicate the use of transcranial magnetic stimulation
* Implanted pacemaker or metal contraindicating MRI-scan